Journal of Ophthalmology / 2020 / Article / Tab 3

Research Article

Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 3

Effect of treatment on BCVA, CMT, and TMV values in the nonvitrectomized group (n = 17).

Mean ± SDF value valuePartial eta2

BCVA (logMAR)
Baseline0.51 ± 0.264.6450.0020.225
6th month0.39 ± 0.26
12th month0.41 ± 0.25
18th month0.41 ± 0.24
24th month0.40 ± 0.22

CMT (μm)
Baseline342 ± 984.6480.0020.225
6th month288 ± 93
12th month266 ± 111
18th month288 ± 97
24th month253 ± 97

TMV (mm3)
Baseline9.04 ± 1.287.3630.0010.315
6th month8.43 ± 1.04
12th month8.36 ± 1.10
18th month8.40 ± 0.95
24th month8.01 ± 0.79

BCVA was measured with a standard Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR) units. BCVA indicates best-corrected visual acuity; CMT, central macular thickness; SD, standard deviation; TMV, total macular volume. Repeated measure ANOVA. Other than BCVA values from baseline to the 6th month of treatment, CMT values from baseline to the 12th month of the treatment, and TMV values from baseline to the 12th month and from baseline to the 24th month of the treatment, pairwise comparisons for BCVA, CMT, and TMV values were not significant in the nonvitrectomized group.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.